[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"FA Corporation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100651473","safety-and-efficacy-of-a-2910-nm-fractional-ablative-fiber-laser-ultraclear-for-improvements-of-skin-laxity-and-lifting-of-the-lower-face-submental-and-neck-treatment-areas-100651473",false,"NCT07759817","Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas","UC 29-2026","Inclusion Criteria:\n\n1. Fitzpatrick skin types I-III participants with Fitzpatrick Skin Types IV-VI may be enrolled only at the investigator's discretion, based on individualized risk assessment documenting skin tone-related risk of post-inflammatory hyperpigmentation, wound healing history, and prior response to ablative or energy-based treatments. Risk assessment documentation must be retained in the participant's study file. Male or female.\n2. Participants must be between 35 and 65 years of age.\n3. Participants must have the ability to receive two lower face and full neck resurfacing laser treatments with desire for improvement in lifting and skin laxity.\n4. Participants must read, understand, and sign the Informed Consent Form.\n5. Participants must be willing and able to comply with all follow-up visit requirements.\n6. Participants must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator.\n7. Participants must be rated as (2) Moderate Sagging to (4) Very Severe Sagging based on the Merz Jawline Grading Scale (MJGS)\\[11\\].\n8. Participants must be rated as a (C) Grade 3: moderate laxity, (D) Grade 4: moderate to severe laxity or (E) Grade 5: severe laxity of the tissues of the neck based on the 5-Grade IBSA Neck Laxity Scale \\[12\\]\n9. Participants of childbearing potential must have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study.\n10. Participants agree to maintain stable body weight, defined as no planned weight-loss program and no significant change in body weight (±10 lbs or ±5%) within 3 months prior to enrollment and throughout study participation.\n11. Participants identified as an appropriate candidate for study treatment based on principal investigator's opinion.\n\nExclusion Criteria:\n\n1. Participants must not have active localized or systemic infections.\n2. Participants must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atopic dermatitis or immunologic abnormalities such as vitiligo.\n3. Participants must not be current smoker or have history of regular tobacco or nicotine use within 12 months prior to enrollment.\n4. Participants must not have had treatments with systemic steroids or systemic retinoids in the 4-months prior to enrollment.\n5. Participants must not have had treatments with 5FU, diclofenac, imiquimod or PDT within 1-month prior to enrollment.\n6. Participants must not have severe or cystic facial acne; currently taking Accutane or have taken Accutane within the last 1-month.\n7. Participants must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications.\n8. Participants must not have had previous surgery and\u002For fat transfer in the treatment area within the last 6-months.\n9. Participant must not have had injectable soft tissue fillers within the last 12-months in the treatment area.\n10. Participant must not have had Poly-L-Lactic acid (PLLA) or Calcium Hydroxylapatite (CaHA) fillers within the last 2 years in the treatment area.\n11. Participant must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area.\n12. Participants must not have had neurotoxins within the last 4-months in the treatment area.\n13. Participant must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12-months.\n14. Participant must not have had a pulse dye or vascular laser, non-ablative laser, microneedling or RF microneedling treatments in the treatment area within the last 3-months.\n15. Participant must not have had an ultrasound treatment such as HIFU, monopolar RF energy-based devices, ablative laser treatments in the treatment area within the last 6-months.\n16. Participants must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.\n17. Participant must not have active sunburn or excessively tanned skin.\n18. Participants must not be pregnant or planning to become pregnant, have given birth less than 3-months ago, and\u002For breastfeeding during the study. Participants of childbearing potential will be asked to confirm they are not pregnant at screening, at each treatment visit and at Visit 6: Day 139 ± 7 days (3-month follow-up) representing approximately 90 days following the second treatment and Visit 7: Day 229 ± 7 days (6-month follow-up).",true,"ALL","35 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates the safety and effectiveness of the UltraClear® 2,910 nm fractional ablative fiber laser for improving skin laxity and tissue lifting in the lower face, submental, and neck areas. Up to 50 adults ages 35-65 will receive two laser treatments approximately 7 weeks apart at two clinical sites. Outcomes will be assessed approximately 90 days after the second treatment using photographic analysis and investigator- and participant-reported improvement scales.",[28,29],"Skin Laxity (Submental and Neck)","Skin Lifting and Tightening","NOT_YET_RECRUITING","2026-08-09",{"date":33,"type":34},"2026-08-12","ACTUAL",{"date":36,"type":22},"2026-08-07",{"date":38,"type":22},"2027-08-31",{"name":40,"class":41},"FA Corporation","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100612538","safety-and-efficacy-of-2910-nm-fiber-laser-resurfacing-and-laser-coring-100612538","NCT07254884","Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring","Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring Treatment to Lift the Eyebrow, Submental Lax Tissue and Address Advanced Signs of Facial Aging","Inclusion Criteria:\n\n* Fitzpatrick skin type I-VI\n* Male or female\n* Subjects must be between 45 and 85 years of age\n* Subjects must have the ability to receive two and up to three full face and upper neck resurfacing laser treatments (pending PI discretion) with desire to lift facial lax skin, submental and\u002For to lift the eyebrow area and\u002For improve facial wrinkles appearance\n* Subjects must read, understand, and sign the Informed Consent Form\n* Subjects must be willing and able to comply with all follow-up visit requirements\n* Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator\n* Subjects must be rated as (2) Moderate Sagging to (4) Very Severe Sagging based on the Merz Scale: Jawline at Rest\n* Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion\n* Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study\n\nExclusion Criteria:\n\n* Subjects must not have active localized or systemic infections\n* Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atopic dermatitis or immunologic abnormalities such as vitiligo\n* Subjects must not be current smoker or have significant history of smoking\n* Subjects must not have had treatments with systemic steroids or systemic retinoids in the 4-months prior to enrollment\n* Subjects must not have had treatments with 5FU, diclofenac, imiquimod or PDT within 1-month prior to enrollment\n* Subjects must not have severe or cystic facial acne; currently taking Accutane or have taken Accutane within the last 1-month\n* Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications\n* Subjects must not have had previous surgery and\u002For fat transfer in the treatment area within the last 6-months\n* Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area\n* Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area\n* Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area\n* Subjects must not have had neurotoxins within the last 4-months in the treatment area\n* Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12-months\n* Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling or RF microneedling treatments in the treatment area within the last 3-months\n* Subject must not have had an ultrasound treatment such as HIFU, monopolar RF energy-based devices, ablative laser treatments in the treatment area within the last 6-months\n* Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia\n* Subject must not have active sunburn or excessively tanned skin\n* Subjects must not be pregnant or planning to become pregnant, have given birth less than 3 months ago, and\u002For breastfeeding during the study","45 Years","85 Years",{"count":53,"type":22},40,[25],"The primary objective of this clinical trial is to evaluate the safety and effectiveness of the 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical) for non-invasive dermatological aesthetic treatment of three facial regions: eyebrow lift (Region 1), submental tissue lift (Region 2), and improvement of rhytids and skin laxity in the cheeks, midface, and jawline (Region 3).",[57,58],"Rhytids","Skin Laxity",[60,61,62,57],"Eyebrow Lift","Submental Tissue Lift","Wrinkles","2025-11-20",{"date":65,"type":34},"2025-11-28",{"date":67,"type":22},"2025-11",{"date":69,"type":22},"2026-11",{"name":40,"class":41},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100610039","2910-nm-erbium-doped-fluoride-fiber-glass-laser-for-the-treatment-of-advanced-perioral-lines-and-wrinkles-100610039","NCT07222397","2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles","Evaluation of the 2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles","Inclusion Criteria:\n\n1. Fitzpatrick skin type I-IV.\n2. Male or female.\n3. Subjects must be between 50 and 80 years of age.\n4. Subjects must have the ability to receive up to two full face resurfacing laser treatment with specific focus on advanced perioral lines and wrinkles.\n5. Subjects must read, understand, and sign the Informed Consent Form.\n6. Subjects must be willing and able to comply with all follow-up visit requirements.\n7. Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator.\n8. Subjects must be rated as Class II or Class III based on the Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS).\n9. Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion.\n10. Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study.\n\nExclusion Criteria:\n\n1. Subjects must not have active localized or systemic infections.\n2. Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atrophic dermatitis or immunologic abnormalities such as vitiligo.\n3. Subjects must not have had treatments with 5FU, diclofenac, imiquimod, steroids, retinoids, or PDT within 1-month prior to enrollment.\n4. Subjects must not currently be taking Accutane or have taken Accutane within the last 1-month.\n5. Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications.\n6. Subjects must not have had previous surgery and\u002For fat transfer in the treatment area within the last 6-months.\n7. Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area.\n8. Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area.\n9. Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area.\n10. Subjects must not have had neurotoxins within the last 3-months in the treatment area.\n11. Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12 months.\n12. Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling, or energy-based device treatment in the treatment area within the last 3 months.\n13. Subject must not have had an ablative laser treatment in the treatment area within the last 6 months.\n14. Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.\n15. Subject must not have active sunburn or excessively tanned skin.\n16. Subjects must not be pregnant or breastfeeding, think they may be pregnant or are trying to get pregnant during the study.","50 Years","80 Years",{"count":81,"type":22},20,[25],"The primary objective is to assess the efficacy, safety and satisfaction associated with the resurfacing treatment of perioral lines and wrinkles with the 2,910 nm mid-infrared Fiber Laser (UltraClear, Acclaro Medical) using both superficial epidermis ablation capabilities and the deep ablative and coagulative capabilities into the dermis for rejuvenation.\n\nParticipants will receive up to two treatments spaced 6-8 weeks apart, followed by a 1-month and 3-month follow-up visit during which the device will be evaluated for its effectiveness defined as improvement addressing perioral lines and wrinkles utilizing multiple scales completed by the investigator and blinded Independent Photographic Reviewers (IPRs). Additionally, safety, subjective overall aesthetic improvement and satisfaction will be monitored and tracked.",[85,57,86,87],"Photodamaged Skin","Lines Skin","Wrinkles and Rhytides","RECRUITING","2025-10-27",{"date":91,"type":34},"2025-10-29",{"date":93,"type":34},"2025-03-01",{"date":95,"type":22},"2026-02",{"name":40,"class":41},1,""]